The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 14, 2012

Filed:

Jan. 28, 2011
Applicants:

Nicholas D. Cosford, San Diego, CA (US);

Thomas J. Seiders, San Diego, CA (US);

Joseph Payne, Oceanside, CA (US);

Jeffrey R. Roppe, Temecula, CA (US);

Dehua Huang, San Diego, CA (US);

Nicholas D. Smith, San Diego, CA (US);

Steve F. Poon, Pasadena, CA (US);

Chris King, Carlsbad, CA (US);

Brian W. Eastman, San Diego, CA (US);

Bowei Wang, Westfield, NJ (US);

Jeannie M. Arruda, LaJolla, CA (US);

Jean-michel Vernier, Laguna Niguel, CA (US);

Xiumin Zhao, San Diego, CA (US);

Inventors:

Nicholas D. Cosford, San Diego, CA (US);

Thomas J. Seiders, San Diego, CA (US);

Joseph Payne, Oceanside, CA (US);

Jeffrey R. Roppe, Temecula, CA (US);

Dehua Huang, San Diego, CA (US);

Nicholas D. Smith, San Diego, CA (US);

Steve F. Poon, Pasadena, CA (US);

Chris King, Carlsbad, CA (US);

Brian W. Eastman, San Diego, CA (US);

Bowei Wang, Westfield, NJ (US);

Jeannie M. Arruda, LaJolla, CA (US);

Jean-Michel Vernier, Laguna Niguel, CA (US);

Xiumin Zhao, San Diego, CA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 25/00 (2006.01); A61K 31/44 (2006.01); C07D 417/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.


Find Patent Forward Citations

Loading…